Food and Drug Administration described

This web page of the Food and Drug Administration describes trans fats and also shows a listing oftrans fats found in common food. Also noted is that the average daily trans fat intake for the American adult is 5-8 grams, which is 2.6percent of daily consumed Calories. 

The current bioequivalence regulations of the US Food and Drug Administration describe several types of experimental approaches in addition to those involving human testing. ... 

GHB has been used both for legitimate clinical and chnical research purposes and for a range of iUicit purposes. It was marketed legally in the United States until 1990, when the U.S. Food and Drug Administration (FDA) banned its sale to consumers. Except for the one indication described later in this section, GHB is a Schedule I controlled substance without other FDA-approved indications. The FDA has also declared y-butyrolactone (GBL) as a List I chemical and 1,4-butanediol (1,4-BD) as a Class I health hazard, practically designating these GHB precursors, which are also industrial solvents, as illicit and unapproved new drugs (National Institute on Drug Abuse 2000). 

Drs. S.Y. Yeh, Thomas R. Insel, John Sharkey, and Michael J. Kuhar contributed to various aspects of the work described. Supported in part by the U.S. Food and Drug Administration. 

Davidow (19), of the Food and Drug Administration, has described a colorimetric method applicable to technical chlordan. The method is based on the observation that when technical chlordan is heated with a mixture of diethanolamine and methanolic potassium hydroxide, a purple color is produced. When known amounts of this insecticide were added to cabbage, pears, and fresh and rancid rat fat, recoveries of 74 to 104% of the insecticide were obtained. However, because two crystalline isomers of chlordan isolated from the technical product do not give a colored reaction product with the reagent, further investigation of the method is being made. The red color obtained when technical chlordan is heated with pyridine, alcoholic alkali, and ethylene glycol monoethyl ether, as described by Ard (2), likewise fails with the crystalline isomers of this insecticide. 

Oxytetracycline is a broad-spectrum antibiotic, which has been used worldwide in veterinary medicine and in aquaculture for the prevention and treatment of disease and as feed additives to promote growth. The maximum residue limits (MRLs) of OTC and relative substances as described by the US Food and Drug Administration [66] and European Union [67] are presented in Table 4. 

The cautious approach to drug approval, as overseen by the federal Food and Drug Administration (FDA), has been described in detail elsewhere (Findlay, 1999). The risks and benefits of a new drug submitted for FDA approval are rigorously studied through randomized, controlled clinical trials. Despite the enormous effort put forth to study new drugs, and the huge financial investment required to support clinical trials, many questions are often left unanswered by the relatively small-scale preapproval studies that may fail to detect, or fully describe, low-incidence adverse effects. These adverse effects may become evident within the months or years immediately... 

The modeling discussed here depends on being able to describe the entire concentration-time curve. This can only be done using a Level A IVIVC (i.e., a point-to-point relationship between in vitro release and in vivo release/absorption). In fact, the U.S. Food and Drug Administration (FDA) defines a Level A IVIVC as a predictive mathematical model for the relationship between the entire in vitro dissolution-release time course and the entire in vivo response time course. 

The company tiles an IND with the U.S. Food and Drug Administration (FDA) seeking permission to test compound in humans, and describing results ot preclinical tests. The IND automatically becomes effective unless the FDA rejects it within 30 days. 

Food and Drug Administration scientists evaluate the safety studies to determine whether or not the results support a conclusion that the product can be used safely. Until the mid-1970s, the underlying assumption in the agency review was that the reports submitted to the agency accurately described study conduct and precisely reported the study data. A suspicion that this assumption was mistaken was raised in the agency s review of studies submitted by a major pharmaceutical manufacturer in support of new drug applications for two important therapeutic products. Review scientists observed data inconsistencies and evidence of unacceptable laboratory practices in the study reports. 

---